Optical genome mapping refines diagnosis of high-grade myeloid neoplasms through detection of MECOM rearrangements cryptic to conventional karyotype.
A new imaging technique found twice as many hidden genetic changes in blood cancers that standard tests miss, enabling better diagnosis and prognosis for patients.
Optical genome mapping detected MECOM rearrangements in 4.7% of 252 consecutive high-grade myeloid neoplasm specimens, doubling the detection rate by identifying 6 cryptic cases completely missed by conventional karyotype and FISH. Resolution of diverse partner loci enabled diagnostic and prognostic reclassification in 5 cases, supporting OGM integration as a standard component of AML cytogenomic workup.
What the study was
- Study design
- cohort_study
- Population
- 252 consecutive high-grade myeloid neoplasm specimens including 224 AML, University of British Columbia
- Sample size
- 252
- Category
- Hematologic Malignancies
- Maturity
- Validated
- Journal
- Am J Clin Pathol
Why it surfaced
OGM doubled MECOM-r detection vs karyotype+FISH in 252 consecutive AML specimens; 6 cryptic high-risk rearrangements missed by standard cytogenetics; partner locus resolution enabled risk reclassification in 5 cases; strong case for OGM integration into HGMN diagnostic workflow.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.